Stanford Alzheimer's Disease Research Center

斯坦福阿尔茨海默病研究中心

• 批准号: 9922029
• 负责人: Victor Henderson
• 金额: $ 301.54万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9922029
• 关键词: Adult; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Area; Artificial Intelligence; Big Data; Bioinformatics; Biological Markers; Biometry; Blood; Brain; Brain imaging; Cell Line; Cells; Clinical; Clinical Management; Cognitive aging; Communities; Consent; Consultations; Data; Data Set; Development; Diagnosis; Disease; Early Diagnosis; Elderly; Family; Feces; Fibroblasts; Foundations; Funding; Future; Goals; Hispanics; Human Resources; Image; Immune; Impaired cognition; Latino; Lewy Bodies; Lewy Body Dementia; Lewy body pathology; Lewy neurites; Link; Liquid substance; Meninges; Mission; Molecular; Nerve Degeneration; Neurodegenerative Disorders; Parkinson Disease; Participant; Pathogenesis; Pathologic; Phenotype; Plasma; Population; Proteomics; Research; Research Personnel; Research Support; Research Training; Resistance; Resource Sharing; Resources; Risk; Skin; Solid; Structure; Therapeutic; Training Support; Training and Education; alpha synuclein; brain tissue; cognitive development; data management; ethnic minority population; high risk; improved; innovation; insight; investigator training; microbiome; motor impairment; multidisciplinary; neuroimaging marker; neuropathology; outreach; pre-clinical; prevent; racial minority; ranpirnase; recruit; repository; resilience; statistics; stool sample; tool; whole genome

1. SUMMARY (Overall) The National Alzheimer's Project Act establishes an integrated national plan to overcome Alzheimer's disease (AD); develop treatments to prevent, halt, or reverse the course of AD; improve the early diagnosis of AD; and decrease disparities in AD for ethnic and racial minority populations at higher risk for AD. In this context, AD is intended to encompass AD-related dementias, including dementia with Lewy bodies. In support of the goals and research milestones of the National Alzheimer's Project Act, the mission of the Stanford Alzheimer's Disease Research Center (ADRC) is to serve as a shared resource to facilitate and enhance research on AD and the spectrum of cognitive impairment associated with Lewy body (LB) pathology. We follow a strategy of deep phenotyping, believing that critical answers emerge more readily when investigators are able to delve deeply within and across multiple levels of participant data. Healthy adults without cognitive or motor impairment serve both as a comparison (control) population and as a preclinical population in which mechanisms of cognitive aging and clinical transition can be studied. People with Parkinson's disease without cognitive impairment also serve as comparators and as an at-risk transitional population for the development of cognitive impairment linked to LB pathology. ADRC resources will provide investigators with unique opportunities for the parallel study of these two neurodegenerative disorders, enabling insights into pathogenesis, preclinical diagnosis, transitions, resistance and resilience, and therapeutic approaches. Aims of the Stanford ADRC are to (1) provide an administrative structure that advances the mission of the center; (2) develop and maintain human resources for studies of the AD spectrum and the LB spectrum of cognitive impairment, as well as cognitive aging; (3) make available well-characterized brain tissues, brain-derived biospecimens, and quantitative molecular data derived from high-content imaging of brain tissues; (4) make available participant biospecimens and high-content biospecimen data; (5) provide structural, functional, and molecular neuroimaging biomarkers in support of research on AD-spectrum cognitive impairment, LB-spectrum cognitive impairment, and cognitive aging; (6) provide for the management of Stanford ADRC data, prepare research datasets, provide high-level biostatistical consultation for ADRC investigators, and support research on big data using tools from biostatistics, bioinformatics, and artificial intelligence; (7) with our community partners, provide respectful, culturally sensitive outreach and provide opportunities for education, training, and research participation for healthy adults, people with AD-spectrum and LB-spectrum disorders, and their families. Stanford ADRC outreach and community engagement extends particularly to urban Hispanic/Latino older adults, an important Bay Area population, which is under-represented in AD-related research; and (8) support the training of investigators and future leaders in the field of AD and related dementia.

1.总结（总体） 《国家阿尔茨海默病项目法》建立了一个克服阿尔茨海默病的综合国家计划 (AD)开发预防、阻止或逆转AD病程的治疗方法;改善AD的早期诊断;以及 减少AD风险较高的少数民族和种族人群的AD差异。在这种情况下，AD 旨在涵盖AD相关痴呆，包括路易体痴呆。支持千年发展目标 和研究里程碑的国家阿尔茨海默氏症项目法案，使命的斯坦福大学阿尔茨海默氏症 疾病研究中心（ADRC）将作为一个共享资源，以促进和加强对AD的研究 以及与路易体（LB）病理学相关的认知损害的范围。我们遵循的战略是 深入的表型分析，相信当研究人员能够深入研究时， 深入到参与者数据的多个层面。无认知或运动功能的健康成人 损伤既作为比较（对照）群体又作为临床前群体，其中 可以研究认知老化和临床转变的机制。帕金森病患者没有 认知障碍也可作为比较对象，并作为发展的风险过渡人群。 与LB病理相关的认知障碍。ADRC资源将为调查人员提供独特的 这两种神经退行性疾病的平行研究的机会，使洞察 发病机理、临床前诊断、转变、抗性和恢复力以及治疗方法。目标 斯坦福大学ADRC将（1）提供一个推进中心使命管理结构;（2） 开发和维护AD谱和认知的LB谱研究的人力资源 损害，以及认知老化;（3）提供良好表征的脑组织，脑源性 生物标本，和定量分子数据来源于高内容成像的脑组织;（4）使 可用的参与者生物标本和高含量的生物标本数据;（5）提供结构，功能， 分子神经影像学生物标志物支持AD-谱系认知障碍研究 认知障碍和认知老化;（6）提供管理斯坦福大学ADRC数据，准备 研究数据集，为ADRC调查人员提供高水平的生物统计咨询，并支持研究 使用生物统计学，生物信息学和人工智能工具的大数据;（7）与我们的社区 合作伙伴，提供尊重，文化敏感的外联活动，并提供教育，培训和 健康成年人、AD谱系和LB谱系障碍患者及其 家庭斯坦福大学ADRC的外展和社区参与特别扩展到城市西班牙裔/拉丁裔 老年人，一个重要的湾区人口，在AD相关研究中代表性不足;以及（8） 支持AD和相关痴呆领域的研究人员和未来领导者的培训。